Close

BioCryst (BCRX) Receives Additional $2.5M of Funding for BCX4430 Development

December 30, 2013 6:57 AM EST Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login